

Special Issue

Targeting the Ubiquitin Pathway in Cancer

Message from the Guest Editor

The ubiquitin–proteasome system (UPS) is a common mechanism by which cells renew their intracellular proteins and maintain protein homeostasis. Recently, abnormal regulation of UPS has been found to be involved in various diseases, including cancer. A series of enzymes known as E1s (ubiquitin-activating enzymes), E2s (ubiquitin-conjugating enzymes), various E3s (ubiquitin ligases), and deubiquitinating (DUB) enzymes in the UPS could serve as potential drug targets in cancers. In addition, chimeric small molecules which are designed to induce degradation of their target proteins via the UPS can be used for cancer therapy. In this Special Issue, we focus on abnormalities of the ubiquitin–proteasome system and their potential of therapeutic target in cancer.

Guest Editor

Prof. Dr. Yasusei Kudo

Department of Oral Molecular Pathology, Tokushima University
Graduate School of Biomedical Sciences, 3-18-15 Kuramoto,
Tokushima 770-8504, Japan

Deadline for manuscript submissions

closed (30 June 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/29725

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)